163 related articles for article (PubMed ID: 17601444)
1. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (acular LS) and nepafenac 0.1% (nevanac) in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD; Amico LM
Am J Ophthalmol; 2007 Jul; 144(1):146-7. PubMed ID: 17601444
[TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
[TBL] [Abstract][Full Text] [Related]
3. Re: Prostaglandin E(2) inhibition and aqueous concentration of ketorolac 0.4% and nepafenac 0.1% in patients undergoing phacoemulsification.
Walters T
Am J Ophthalmol; 2007 Dec; 144(6):978-9; author reply 979-80. PubMed ID: 18036883
[No Abstract] [Full Text] [Related]
4. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
[TBL] [Abstract][Full Text] [Related]
6. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS
Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
[TBL] [Abstract][Full Text] [Related]
7. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
Duong HV; Westfield KC; Chalkley TH
J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Sep; 34(9):1509-12. PubMed ID: 18721711
[TBL] [Abstract][Full Text] [Related]
9. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation.
Trattler W; McDonald M
Cornea; 2007 Jul; 26(6):665-9. PubMed ID: 17592313
[TBL] [Abstract][Full Text] [Related]
10. Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Bucci FA; Waterbury LD
J Cataract Refract Surg; 2008 Aug; 34(8):1226; author reply 1226-7. PubMed ID: 18655957
[No Abstract] [Full Text] [Related]
11. Prostaglandin E
Acar U; Acar DE; Tanriverdi C; Acar M; Ozdemir O; Erikci A; Ornek F
Ocul Immunol Inflamm; 2017 Jun; 25(3):323-327. PubMed ID: 26765265
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of the nonsteroidal anti-inflammatory drug nepafenac on corneal sensory nerve fibers responding to chemical irritation.
Acosta MC; Luna C; Graff G; Meseguer VM; Viana F; Gallar J; Belmonte C
Invest Ophthalmol Vis Sci; 2007 Jan; 48(1):182-8. PubMed ID: 17197531
[TBL] [Abstract][Full Text] [Related]
13. Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Bucci FA; Waterbury LD
Adv Ther; 2009 Jun; 26(6):645-50. PubMed ID: 19568702
[TBL] [Abstract][Full Text] [Related]
14. Effects of nonsteroidal ophthalmic drops on epithelial healing and pain in patients undergoing bilateral photorefractive keratectomy (PRK).
Durrie DS; Kennard MG; Boghossian AJ
Adv Ther; 2007; 24(6):1278-85. PubMed ID: 18165210
[TBL] [Abstract][Full Text] [Related]
15. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
16. Aqueous humor penetration of ketorolac formulated in DuraSite or DuraSite 2 delivery systems compared to Acular LS in rabbits.
Shafiee A; Bowman LM; Hou E; Hosseini K
J Ocul Pharmacol Ther; 2013 Nov; 29(9):812-6. PubMed ID: 23992042
[TBL] [Abstract][Full Text] [Related]
17. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
Jones BM; Neville MW
Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
[TBL] [Abstract][Full Text] [Related]
18. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
Sahu S; Ram J; Bansal R; Pandav SS; Gupta A
J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
[TBL] [Abstract][Full Text] [Related]
19. Reduction of vitreous prostaglandin E2 levels after topical administration of ketorolac 0.45%.
Schoenberger SD; Kim SJ; Sheng J; Calcutt MW
JAMA Ophthalmol; 2014 Feb; 132(2):150-4. PubMed ID: 24264034
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
Tzelikis PF; Vieira M; Hida WT; Motta AF; Nakano CT; Nakano EM; Alves MR
Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
